Each state might look a little different, but Medicaid in all states is moving toward some kind of managed care, stated Matt Salo. And a newly proposed rule from CMS regulating access, enrollment, financing and more is an attempt to get everyone on the same page. But some people are concerned that this rule will stifle innovation in the states, Salo said.
People are appropriately distrustful, though, according to Margaret E. O’Kane, MHA, because it’s a new way of doing things and the success of managed care depends on a “vigorous accountability agenda.”
“There’s going to be a lot of pushback from people that are used to working only in fee-for-service and in a different situation,” she said.
Access to care for Medicaid has been a longstanding issue, Austin Frakt, PhD, said, and it remains a complex one because there are a variety of ways to measure access. The new regulations were concerning, in a way, because he found them vague, and that they put a lot of the burden back on states to put a plan in place for standards to measure access to care without specifying what it should look like.
The National Committee for Quality Assurance will be monitoring the situation, O’Kane said, especially since the industry has been in a period of very broad networks, and now the discussion is about narrow networks.
“It’s kind of a new day for us,” she said.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More